Abstract:Acute myeloid leukemia (AML) is a group of heterogeneous diseases. Abnormalities in genes that encode transcription factors and tyrosine kinases represent two classes of the most frequently detected genetic events in human AMLs. Recently, a new category of gene mutations associated with epigenetic regulation have also been proposed. Recurrent somatic mutations of DNMT3A were identified in 23 of 112 (20.5%) cases using exome sequencing technique. The DNMT3A mutants showed reduced enzymatic activity or aberrant affinity to histone H3 in vitro. Gene expression profiles and DNA methylation patterns showed some differences between patients with and without DNMT3A mutations. Notably, we found that members of HOXB genes were extensively upregulated with mutations of DNMT3A, and hypomethylation of certain CpG islands in the HOXB locus. DNMT3A mutations enabled 32D cells to acquire growth and survival advantage with and without IL3. Leukemias with DNMT3A mutations constituted a group of poor prognosis with elderly disease onset. These data suggest a contribution of aberrant DNA methyltransferase activity to the pathogenesis of acute monocytic leukemia and provides a useful new biomarker for relevant cases. We performed the study to systemically investigate the frequencies and the prognostic relevance of previously known genetic events and newly established molecular markers in a large series of 1,185 adult AML patients. In particular, we intent to stratify the AML patients who lacked cytogenetic prognostic markers into appropriate prognostic groups. Multivariate analysis identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event free survival (EFS), while bi-allelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in whole group and younger patients aged less than 60 years. Further studies will be focused on using different treatment strategies according to AML genotypes. Acute myeloid leukemia (AML) is a group of heterogeneous diseases. Abnormalities in genes that encode transcription factors and tyrosine kinases represent two classes of the most frequently detected genetic events in human AMLs. Recently, a new category of gene mutations associated with epigenetic regulation have also been proposed. Recurrent somatic mutations of DNMT3A were identified in 23 of 112 (20.5%) cases using exome sequencing technique. The DNMT3A mutants showed reduced enzymatic activity or aberrant affinity to histone H3 in vitro. Gene expression profiles and DNA methylation patterns showed some differences between patients with and without DNMT3A mutations. Notably, we found that members of HOXB genes were extensively upregulated with mutations of DNMT3A, and hypomethylation of certain CpG islands in the HOXB locus. DNMT3A mutations enabled 32D cells to acquire growth and survival advantage with and without IL3. Leukemias with DNMT3A mutations constituted a group of poor prognosis with elderly disease onset. These data suggest a contribution of aberrant DNA methyltransferase activity to the pathogenesis of acute monocytic leukemia and provides a useful new biomarker for relevant cases. We performed the study to systemically investigate the frequencies and the prognostic relevance of previously known genetic events and newly established molecular markers in a large series of 1,185 adult AML patients. In particular, we intent to stratify the AML patients who lacked cytogenetic prognostic markers into appropriate prognostic groups. Multivariate analysis identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event free survival (EFS), while bi-allelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in whole group and younger patients aged less than 60 years. Further studies will be focused on using different treatment strategies according to AML genotypes.

Progressive Chromatin Repression and Promoter Methylation of A-Catenin Correlates with AML Transformation in Patients with and Without 5q Deletions.

Methylation Analysis of the Wnt Antagonist in Myelodysplastic Syndrome

A Distinct Epigenetic Signature at Targets of a Leukemia Protein

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

C/Ebpa Gene Mutation and C/Ebpa Promoter Hypermethylation in Acute Myeloid Leukemia with Normal Cytogenetics.

Acute Myeloid Leukemia with deletion 5q is an epigenetically distinct subgroup defined by heterozygous loss of KDM3B

m5C methylation modification guides the prognostic value and immune landscapes in acute myeloid leukemia

m5C regulator‐mediated methylation modification patterns and tumor microenvironment infiltration characteristics in acute myeloid leukemia

Beta-Catenin Is A Candidate Therapeutic Target For Myeloid Neoplasms With Del(5q)

Mutations of Epigenetic Modifier Genes As A Poor Prognostic Factor in Acute Promyelocytic Leukemia under Treatment with All-Trans Retinoic Acid and Arsenic Trioxide

A Dysregulated DNA Methylation Landscape Linked to Gene Expression in MLL-Rearranged AML

CLEC11A methylation is correlated to AML subtypes and cytogenetic risk factors but not patient demographics

Methylation profiling in acute myeloid leukemia

Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia

A novel epigenetic mini-circuitry contributes to t(8;21) leukaemogenesis.

Genetic and epigenetic changes contributing to leukemogenesis and prognostic impact in acute myeloid leukemia

Non-Mutational Changes of Autophagy Marker LC3A in Patients with Acute Myeloid Leukemia; Effect of DNA Methylation and Expression Level of LncRNA-GAS5 and miRNA-155-5p, A Case Control Study

DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia

Comprehensive DNA Methylation-transcriptome Profiles Association Analysis During the Treatment of Acute Myelocytic Leukemia

The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation

Crosstalk between genomic variants and DNA methylation in FLT3 mutant acute myeloid leukemia